Lenalidomide and Disturbance in attention - a phase IV clinical study of FDA data

Summary:

Disturbance in attention is reported as a side effect among people who take Lenalidomide (lenalidomide), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Dexamethasone, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Disturbance in attention when taking Lenalidomide. It is created by eHealthMe based on reports of 52,873 people who have side effects when taking Lenalidomide from the FDA, and is updated regularly.

What is Lenalidomide?

Lenalidomide has active ingredients of lenalidomide. eHealthMe is studying from 52,881 Lenalidomide users. Check the latest studies of Lenalidomide.

What is Disturbance in attention?

Disturbance in attention is found to be associated with 1,770 drugs and 1,970 conditions by eHealthMe. Check the latest studies of Disturbance in attention.

On Aug, 08, 2026

52,873 people reported to have side effects when taking Lenalidomide.
Among them, 61 people (0.12%) have Disturbance in attention.

Could Lenalidomide cause Disturbance in attention?

Among these 61 people:

How long have people been on Lenalidomide when they have Disturbance in attention? *

What is the gender of people who have Disturbance in attention when taking Lenalidomide? *

female: 47.17 %
male: 52.83 %

What is the age of people who have Disturbance in attention when taking Lenalidomide? *

What are other drugs people take besides Lenalidomide? *

What are other side effects people have besides Disturbance in attention? *

Fatigue (feeling of tiredness): 32 people, 52.46%
Dizziness: 22 people, 36.07%
Headache (pain in head): 22 people, 36.07%
Weakness: 21 people, 34.43%
Stress And Anxiety: 21 people, 34.43%
Back Pain: 20 people, 32.79%
Drowsiness: 19 people, 31.15%
Memory Loss: 18 people, 29.51%
Orthostatic Hypotension (a medical condition consisting of a sudden decrease in blood pressure when a person stands up): 17 people, 27.87%
Constipation: 17 people, 27.87%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 35 people, 57.38%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 12 people, 19.67%
Raynaud's Phenomenon (discoloration of the fingers, toes, and occasionally other areas): 4 people, 6.56%
Psychotic Disorder: 4 people, 6.56%
High Blood Pressure: 4 people, 6.56%
Suicide Attempt: 3 people, 4.92%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 3 people, 4.92%
Progressive Multifocal Leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells): 1 person, 1.64%
Partial Seizures (seizures which affect only a part of the brain at onset): 1 person, 1.64%
Monoclonal Gammopathy: 1 person, 1.64%

* Approximation only. Some reports may have incomplete information.

Do you take Lenalidomide and have Disturbance in attention?

- Check whether Disturbance in attention is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lenalidomide:

Lenalidomide (52,881 reports)

Browse all side effects of Lenalidomide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Disturbance in attention:

Disturbance in attention (1,771 drugs)

Browse all the conditions that are associated with Disturbance in attention:

Disturbance in attention (1,970 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lenalidomide (the active ingredients of Lenalidomide) and Lenalidomide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.